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To investigate whether exposure to hyperemesis gravidarum (hyperemesis) is associated




Medical Birth Registry of Norway (1967–2002) linked to the nationwide Cardiovascular Dis-
ease in Norway project 1994–2009 (CVDNOR) and the Cause of Death Registry.
Population
Women in Norway with singleton births from 1967 to 2002, with and without hyperemesis,
were followed up with respect to cardiovascular outcomes from 1994 to 2009.
Methods
Cox proportional hazards regression model was applied to estimate hazard ratios (HRs)
with 95% confidence interval (CI).
Main outcome measures
The first hospitalisation due to nonfatal stroke, myocardial infarction or angina pectoris, or
cardiovascular death.
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Results
Among 989 473 women with singleton births, 13 212 (1.3%) suffered from hyperemesis.
During follow-up, a total of 43 482 (4.4%) women experienced a cardiovascular event. No
association was found between hyperemesis and the risk of a fatal or nonfatal cardiovascu-
lar event (adjusted HR 1.08; 95% CI 0.99–1.18). Women with hyperemesis had higher risk
of hospitalisation due to angina pectoris (adjusted HR 1.28; 95% CI 1.15–1.44). The risk of
cardiovascular death was lower among hyperemetic women in age-adjusted analysis (HR
0.73; 95% CI 0.59–0.91), but the association was no longer significant when adjusting for
possible confounders.
Conclusion
Women with a history of hyperemesis did not have increased risk of a cardiovascular event
(nonfatal myocardial infarction or stroke, angina pectoris or cardiovascular death) compared
to women without.
Introduction
Both the European and American guidelines for prevention of cardiovascular disease (CVD)
in women now include pregnancy-related complications, such as preeclampsia and preg-
nancy-induced hypertension, as risk factors [1,2]. CVD is the leading cause of death in women
[2,3] and early detection of individuals at risk may prevent major cardiovascular events. Preg-
nancy-related risk factors for CVD provide such an opportunity.
Hyperemesis gravidarum (hyperemesis), characterized by extreme nausea and vomiting in
early pregnancy, is the most common reason for hospitalisation in the first trimester of preg-
nancy and is associated with several risk factors for CVD [4,5]. These include low socioeco-
nomic status, hypertension, hypercholesterolemia, overweight, autoimmune diseases such as
rheumatoid arthritis and diabetes mellitus [6–9]. Hyperemesis has also been found associated
with placental dysfunction disorders, i.e. preeclampsia and placental abruption [10–12], both
known risk factors for CVD later in life [13–15]. Whether women with hyperemesis have a
subsequent increased risk of cardiovascular events has to our knowledge not yet been studied.
We therefore aimed to investigate the risk of fatal and nonfatal cardiovascular events during
long-term follow-up in women with and without a history of hyperemesis.
Materials and methods
Study population
From 1967 to 2002, all pregnancies ending after week 16 were registered in the Medical Birth
Registry of Norway (MBRN) [16]. This registration is mandatory and has to be done within
one week after discharge from the delivery unit. Information on maternal health before and
during pregnancy, complications during pregnancy and delivery as well as information about
the infant are registered. The study population comprised women with singleton births of
more than 23 weeks of gestation registered in the MBRN during 1967–2002, being alive in
Norway at the start of follow-up (Fig 1).
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Exposure
From 1967 to 1998, pregnancy complications were reported in the MBRN in free text accord-
ing to the International Classification of Disease (ICD). Women with hyperemesis were regis-
tered with ICD-8 codes 638.0 (hyperemesis gravidarum with neuritis) and 638.9 (hyperemesis
gravidarum without mention of neuritis) until 1998, and from 1999 and onwards hyperemesis
was registered by the ICD-10 codes O21.0 (mild hyperemesis gravidarum), O21.1 (hyperem-
esis gravidarum with metabolic disturbances) and O21.9 (vomiting in pregnancy, unspecified)
[17].
Follow-up
By using the personal identification number unique to every Norwegian resident, data from
the MBRN were linked to the Cause of Death Registry and hospital discharge data on
Fig 1. Flow diagram of the study population. Data on 1 018 478 women with registered pregnancies in the Medical Birth Registry of Norway (MBRN)
in 1967–2002 were available. The figure shows how complete cases at start of follow-up were defined.
https://doi.org/10.1371/journal.pone.0218051.g001
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cardiovascular events obtained from the Cardiovascular Disease in Norway project
(CVDNOR). In CVDNOR (https://cvdnor.b.uib.no/), all hospitalisations due to CVD or dia-
betes mellitus have been collected from all Norwegian somatic hospitals from 1994 through
2009 (1994 was the first year all hospitals in Norway started to use electronic patient adminis-
trative systems). CVDNOR has been described in detail elsewhere [18,19]. Information on
death due to CVD during the same time period was obtained from the Norwegian Cause of
Death Registry, which has a 98% coverage and completeness of the Norwegian population. For
all deaths, a death certificate must be completed by a physician. A code from the ICD system is
allocated to the diagnoses in the death certificate [20]. The registry used ICD-9 from 1986 to
1995 and ICD-10 codes from 1996 to 2009. Women with singleton births registered in the
MBRN during 1967–1994 were followed with respect to cardiovascular outcomes from 1994
through 2009. Women with singleton births registered in the MBRN during 1994–2002 were
followed through 2009.
Outcome
The primary outcome was defined as the occurrence of cardiovascular death, nonfatal myocar-
dial infarction (I21, I22), nonfatal stroke (I60-I61, I63-I64) or hospitalisation due to angina
pectoris (I20, I25.1) as main or secondary discharge diagnosis in a time-to-event analysis. Car-
diovascular death was defined as CVD (I00-I99) as the underlying cause of death registered in
the Cause of Death Registry or death within 28 days after hospitalisation with a cardiovascular
event (I00-I99). Secondary outcome was defined as the primary outcome, excluding angina
pectoris. In addition, separate analyses for each component of the primary outcome were
conducted.
Covariates
Age at first birth was the woman’s age at her first registered birth in the MBRN. Since some
women delivered children before 1967, a parity-variable reflecting the mother’s self-reported
parity was used. Information on maternal country of origin was provided from Statistics
Norway.
Information on gestational hypertension, placental abruption, pre-gestational hypertension
and pre-gestational diabetes mellitus was obtained from the MBRN. Based on information
from each woman’s registered pregnancies, dichotomous variables were created (never/ever).
Information on smoking and maternal body weight was not available.
Information on maternal highest education at the end of follow-up was obtained from Sta-
tistics Norway and categorized as basic (9 years (7 years in the 1960s)), secondary (10–12
years) or tertiary (�13 years), according to the Norwegian Standard Classification of Educa-
tion [21].
Statistical methods
The analyses were conducted in STATA version 15. Descriptive statistics of women with and
without hyperemesis are presented as median (25 and 75 percentiles) or as numbers (%). Cox
proportional hazards regression model was applied to estimate hazard ratios (HRs) for time-
to-event outcomes. Women with previous births, still alive and living in Norway at start of fol-
low-up were followed from 1994 until a CVD event occurred or censored if dead from other
causes, emigration or at the cut-off date of December 31st 2009, whichever occurred first. Since
angina as a discharge diagnosis may be more prone to bias, we also performed the analyses
without angina as a secondary outcome. In addition, the occurrence of a nonfatal myocardial
infarction, nonfatal stroke, angina pectoris or cardiovascular death were assessed individually
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regardless of the order of which the events occurred if a woman had experienced more than
one event during follow-up. The time variable in the Cox-models was “years from 1994 (or
first pregnancy if later than 1994) to the event of interest/censored”. In addition to the crude
analyses, age-adjusted (Model 1) and multivariable-adjusted (Model 2) analyses were per-
formed. Based on prior knowledge [4,6,12,22], the following covariates were considered asso-
ciated with both hyperemesis and the studied outcome, and were included as potential
confounders: the woman’s age at first pregnancy and year of birth, highest obtained education,
country of birth, hypertensive disorders in pregnancy, placental abruption, pre-gestational dia-
betes and pre-gestational hypertension. Less than 1.5% of the women had missing information
on education, information on the other covariates were complete. An estimate with a confi-
dence-interval without one or a p-value below 0.05 was considered statistically significant.
Ethical approval for the study was obtained from the Regional Committee for Medical and
Health Research Ethics (2015/1347/REK South-East). Due to the large number of women reg-
istered in the MBRN and the CVDNOR project, the ethical committee approved the study,
making an exception from the general rule of necessitating consent from all women included.
The data was de-identified to preserve the participants’ privacy.
Additional analyses
The primary outcome was also assessed in a subgroup of women born before 1945. This group
included the oldest women in the study population, aged 50 years or older at start of follow-
up. This was done to investigate if the studied associations differed according to if only women
at the highest risk of a cardiovascular event in the population were included.
Results
Among 1 018 478 women with singleton births during 1967–2002, 9 044 (0.9%) emigrated and
9 690 (1.0%) died before start of follow-up. Less than 1.5% had missing information on covari-
ates and only complete cases were used for analyses (Fig 1). The study sample comprised 989
473 women, of which 13 212 (1.3%) had suffered from hyperemesis in at least one pregnancy.
The median follow-up time was 15 years (range 0–15) and total person-years at risk were 13
527 714. Lost to follow-up because of emigration was 10 360 (1.1%) women and 20 719 (2.1%)
women were censored due to death from other causes during follow-up (1994–2009). Women
with a history of hyperemesis were younger at their first registered pregnancy and were less
often of ethnic Norwegian origin compared to women without hyperemesis. There was no dif-
ference between the two exposure groups in the proportion of women with pre-gestational dia-
betes mellitus or pre-gestational hypertension. Women with a history of hyperemesis were
younger at start of follow-up. At the end of follow-up, women with previous hyperemesis were
younger, had obtained a higher level of education and were more often multipara, compared
to women without hyperemesis (Table 1).
Primary outcome
Among women with a history of hyperemesis, 535 (4.1%) experienced at least one cardiovas-
cular event during follow-up, compared to 42 947 (4.4%) of the women without such history
(Table 2). In the crude analysis, women with hyperemesis had a lower risk of a cardiovascular
event compared to women without such history (Fig 2 and Table 2), but this association was
no longer present after adjustment for age and other available confounders (Table 2). When
the effect of each confounder was considered individually, we found that the change from
Model 1 to Model 2 was mainly driven by the woman’s year of birth.
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Secondary outcomes
After excluding angina as a part of the composite outcome, 319 (2.4%) of the women with a
history of hyperemesis had experienced a cardiovascular event (cardiovascular death, nonfatal
myocardial infarction or stroke) during follow-up, compared to 29 033 (3.0%) of the women
without such history. In the crude analysis there was a lower risk of a cardiovascular event
among women with a history of hyperemesis compared to women without hyperemesis, and
still significantly lower after adjustment for age, but after adjustment for other available con-
founders, the association was no longer significant (Table 2).
Table 1. Characteristics of the study cohort: Women in Norway with singleton births from 1967 to 2002 (n = 989 473).
Maternal and pregnancy characteristics Women with hyperemesis gravidarum
(n = 13 212)
Women without hyperemesis gravidarum
(n = 976 261)
P-value��
At time of delivery
Median age at first pregnancy� 24 (21–27) 25 (21–28) <0.01
Age at first reg. pregnancy, n (%) <0.01
�19 1 574 (11.9) 117 031 (12.0)
20–24 5 677 (43.0) 368 935 (37.8)
25–29 4 136 (31.3) 304 875 (31.2)
30–34 1 333 (10.1) 127 826 (13.1)
�35 492 (3.7) 57 594 (5.9)
Pre-gestational diabetes, n (%) 44 (0.3) 3 672 (0.4) 0.4
Pre-gestational hypertension, n (%) 63 (0.5) 4 386 (0.5) 0.6
Maternal country of origin, n (%) <0.01
Norway 11 565 (87.5) 880 279 (90.2)
Europe 758 (5.7) 57 747 (5.9)
Africa 170 (1.3) 4 853 (0.5)
Asia 507 (3.8) 19 447 (2.0)
North-America 165 (1.3) 10 931 (1.1)
South-America 40 (0.3) 2 517 (0.3)
Oceania 7 (0.1) 487 (0.1)
At start of follow-up
Median age at start of follow-up� 35 (28–45) 37 (29–46) <0.01
At end of follow-up
Median age at the end of study� 50 (42–59) 52 (43–61) <0.01
Min, max age at the end of study 22, 89 19, 91
Highest obtained education, n (%) <0.01
Basic 3 367 (25.5) 248 107 (25.4)
Secondary 5 797 (43.9) 444 304 (45.5)
Tertiary 4 048 (30.6) 283 850 (29.1)
Parity by end of follow-up, n (%) <0.01
Primipara 1 727 (13.1) 201 865 (20.7)
Multipara 11 485 (86.9) 774 396 (79.3)
Preeclampsia, pregnancy-related hypertension and
eclampsia, n (%)
985 (7.5) 73 581 (7.5) 0.7
Placental abruption, n (%) 169 (1.3) 10 911 (1.1) 0.1
�Median with 25 and 75 percentiles
��Tested with t-test or chi-squared test
https://doi.org/10.1371/journal.pone.0218051.t001
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During follow-up, women with a history of hyperemesis had lower risk of cardiovascular
death compared to women without such history (crude HR 0.63; 95% CI 0.51–0.78) (Table 2).
The association was still significantly lower after age-adjustment, but after adjustment for
other available confounders, the association was no longer significant. The risk of nonfatal
myocardial infarction or stroke did not differ according to hyperemesis-status in pregnancy
(Table 2). Women with hyperemesis had a higher risk of being hospitalised with angina pecto-
ris, both in the age-adjusted and multivariable-adjusted model (Table 2).
Additional analyses
Among 165 327 women born before 1945 with a previous pregnancy, 1743 women had suf-
fered from hyperemesis. During 15 years of follow-up, a total of 23 287 (14.1%) women experi-
enced a cardiovascular event (primary outcome). In the subgroup of older women, those with




In this large nationwide cohort study, we found no evidence of increased risk of a cardiovascu-
lar event (nonfatal myocardial infarction or stroke, angina pectoris or cardiovascular death)
long-term in women with hyperemesis compared to those without.
Strengths and limitations
A major strength in this study is the large nationwide study population and the long follow-
up-time for cardiovascular events. The MBRN and the Cause of Death Registry have manda-
tory reporting, and CVDNOR contains information on CVD hospitalisations from all somatic
hospitals in Norway in the time-period. Moreover, the linkage of the MBRN to both CVDNOR
Table 2. Primary and secondary outcomes during 15 years of follow-up (1994–2009) in women with a history of hyperemesis gravidarum (n = 13 212) compared to
women without (n = 976 261) in Norway.
Cardiovascular event Number (%) of women with
events according to HG
status
Hazard ratio (95% confidence interval) for CVD
eventNo HG as referent group
HG
(n = 13 212)
No HG
(n = 976 261)
Crude model Model 1� Model 2��
Primary outcome
CVD death, nonfatal MI, nonfatal stroke or hospitalization with angina pectoris 535 (4.1) 42 947 (4.4) 0.90 (0.83–0.98) 0.98 (0.90–1.07) 1.08 (0.99–1.18)
Main secondary outcome
CVD death, nonfatal MI or nonfatal stroke 319 (2.4) 29 033 (3.0) 0.80 (0.71–0.89) 0.88 (0.78–0.98) 0.96 (0.86–1.08)
Additional secondary outcomes
Death from CVD 81 (0.6) 9 333 (1.0) 0.63 (0.51–0.78) 0.73 (0.59–0.91) 0.81 (0.65–1.01)
Hospitalisation with angina 299 (2.3) 20 151 (2.1) 1.08 (0.96–1.21) 1.16 (1.03–1.30) 1.28 (1.15–1.44)
Nonfatal MI 126 (1.0) 11 063 (1.1) 0.83 (0.69–0.99) 0.90 (0.76–1.08) 1.01 (0.84–1.20)
Nonfatal stroke 163 (1.2) 13 038 (1.3) 0.91 (0.78–1.06) 0.99 (0.85–1.15) 1.07 (0.92–1.25)
HG: hyperemesis gravidarum, CVD: cardiovascular disease, MI: myocardial infarction
�Age-adjusted
��Adjusted for woman’s age at first birth, woman’s year of birth (categorical), country of birth, education, hypertensive disorder in pregnancy, pre-gestational
hypertension, pre-gestational diabetes, placental abruption.
https://doi.org/10.1371/journal.pone.0218051.t002
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and the Cause of Death Registry made it possible to include cardiovascular deaths outside hos-
pital and increase the accuracy by defining cardiovascular death as either death within 28 days
after discharge with a cardiovascular event or CVD as the underlying cause of death on the
death certificate.
Fig 2. Event-free survival during follow-up (1994–2009). Women in Norway with a history of hyperemesis gravidarum (n = 13 212) compared to
women without such history (n = 976 261).
https://doi.org/10.1371/journal.pone.0218051.g002
Table 3. Primary outcome during 15 years of follow-up (1994–2009) in women born before 1945 with a history of hyperemesis gravidarum (n = 1 743) compared to
women without (n = 163 584) in Norway.
Cardiovascular event Number (%) of women with events
according to HG status
Hazard ratio (95% confidence interval) for
CVD eventNo HG as referent group
HG (n = 1
743)
No HG (n = 163
584)
Crude model Model 1� Model 2��
Primary outcome First hospitalisation with MI, stroke or angina pectoris, or
CVD death






HG: hyperemesis gravidarum, CVD: cardiovascular disease, MI: myocardial infarction
�Age-adjusted
��Adjusted for woman’s age at first birth, woman’s year of birth (categorical), country of birth, education, hypertensive disorder in pregnancy, pre-gestational
hypertension, pre-gestational diabetes, placental abruption.
https://doi.org/10.1371/journal.pone.0218051.t003
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The change in estimate from Model 1 to Model 2 was mainly due to the adjustment for
maternal year of birth. This change was also found independent of adjustment for age. We
assessed the difference in effect estimates in different birth cohorts and found slightly different
effect estimates in different strata, but all the HRs pointed to the same overall result with esti-
mates close to one and negative findings. The small change in estimate may be the conse-
quence of a cohort effect [23] because of heterogeneity in follow-up time for events between
young and old segments of the population. The lack of information on cardiovascular events
in the period before 1994 is another limitation. On the other hand, cardiovascular events in
women are most likely to occur after the age of 50 [19,24] and 90% of the women in this study
were younger than 53 years at start of follow-up in 1994, making them less likely to have suf-
fered from a cardiovascular event before follow-up started. Moreover, the uncertainty related
to angina as a discharge diagnosis may have led to inclusion of events representing non-car-
diac chest pain [25]. It is therefore not known whether the increased risk of being hospitalised
due to angina pectoris among women with previous hyperemesis indicates an increased risk of
later ischemic heart disease or not.
Although incorrect registration is a limitation in all register-based research, hyperemesis
in the MBRN has previously been validated and found eligible for large-scale epidemiologi-
cal studies [17]. Moreover, the MBRN did not contain information on potential confound-
ers, such as smoking-habits or body mass index before 1999 and 2006, respectively.
Smoking is associated with a reduced risk of hyperemesis and hyperemesis is associated
with both underweight and obesity [7]. We also lacked information on hypertension, diabe-
tes and cholesterol at start of follow-up. The lack of potential confounder control may have
contributed to residual confounding. However, we have previously shown that hyperemetic
women at the age of 40 have similar cardiovascular risk factor profiles as women without
hyperemesis [26].
Comparison with other studies
Few previous studies have explored cardiovascular risk subsequent to hyperemesis. Some large
population-based studies have, however, found women with a history of hyperemesis to have
increased risk of preeclampsia [10,12] and autoimmune diseases such as rheumatoid arthritis
[9,27]. Immunological abnormalities and increase of fetal cells in maternal circulation may
reflect possible underlying mechanisms, such as abnormal placentation and increased levels of
human chorionic gonadotropin (hCG) [10]. Such mechanisms could also contribute to explain
associations between autoimmune disease and hyperemesis.
Hyperemesis during second trimester is found to be strongly associated with preterm pre-
eclampsia, placental abruption as well as a giving birth to a small-for-gestational-age baby [12].
Despite the fact that all aforementioned conditions are associated with increased risk of CVD
later in life [13,28], we did not find any evidence of increased risk for cardiovascular events
subsequent to hyperemesis. This is, however, in line with findings in our previous articles on
midlife cardiovascular risk factors subsequent to hyperemesis, and on risk of cardiovascular
death among women with a history of hyperemesis [26, 29]. Compared to our previous paper
on long-term mortality following hyperemesis, the slightly lower HR for cardiovascular death
in crude and age-adjusted analyses in the present study may be explained by different follow-
up time and a broader definition of cardiovascular death. In the previous paper cardiovascular
death was defined as CVD as the underlying cause of death registered in the Cause of Death
Registry [29]. In the present paper, we defined cardiovascular death as CVD as the underlying
cause of death registered in the Cause of Death Registry or death within 28 days after hospitali-
sation with a cardiovascular event.
Cardiovascular morbidity following hyperemesis
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Interpretation
Results of the current study indicate that women with a history of hyperemesis do not have
higher risk of cardiovascular events later in life, indicating that they may have the same cardio-
vascular follow-up as the female population in general.
Although the study population was relatively young at the end of follow-up, 25% of the
women were above 60 years and it is unlikely that hyperemesis is associated with increased
risk of a premature cardiovascular event. This assumption is furthermore supported by the
large cohort, number of events and long follow-up time. Additional analyses on women aged
50 years or older at start of follow-up revealed no increase in risk of a cardiovascular event
among women with a history of hyperemesis compared to women without. When conducting
sub-analyses, exploring each cardiovascular event separately, we found that hyperemetic
women had slightly increased risk of being hospitalised due to angina pectoris. The difference
was significant in the adjusted model only, something which makes the interpretation difficult.
Moreover, the diagnostic criteria for myocardial infarction have changed over time, and tropo-
nins were first introduced in Norwegian hospitals in 1999–2001 [30]. This means that women
previously diagnosed with angina, may after introduction of troponins have been diagnosed
with a myocardial infarction. This would, however, probably not have changed the results for
the primary outcome. It is not known whether women with angina in our study have suffered
from a myocardial infarction after follow-up and because of the relatively young population,
this could be a topic for future research.
Conclusion
In this large nationwide cohort study, we found no evidence of increased risk of a cardiovascu-
lar event (nonfatal myocardial infarction or stroke, angina pectoris or cardiovascular death) in
women with a history of hyperemesis compared to women without.
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